Navegando por Autor "Almeida, Raíssa Nóbrega de"
Agora exibindo 1 - 3 de 3
- Resultados por página
- Opções de Ordenação
Artigo Changes in cortisol but not in brain-derived neurotrophic factor modulate the association between sleep disturbances and major depression(2020-04-28) Santiago, Giuliana Travassos Pires; Galvão, Ana Cecília de Menezes; Almeida, Raíssa Nóbrega de; Mota-Rolim, Sergio Arthuro; Palhano-Fontes, Fernanda; Maia-de-Oliveira, João Paulo; Araújo, Dráulio Barros de; Lobão-Soares, Bruno; Galvão-Coelho, Nicole LeiteSleep disturbance is a symptom consistently found in major depression and is associated with a longer course of illness, reduced response to treatment, increased risk of relapse and recurrence. Chronic insomnia has been associated with changes in cortisol and serum brain-derived neurotrophic factor (BDNF) levels, which in turn are also changed in major depression. Here, we evaluated the relationship between sleep quality, salivary cortisol awakening response (CAR), and serum BDNF levels in patients with sleep disturbance and treatment-resistant major depression (n = 18), and in a control group of healthy subjects with good (n = 21) and poor (n = 18) sleep quality. We observed that the patients had the lowest CAR and sleep duration of all three groups and a higher latency to sleep than the healthy volunteers with a good sleep profile. Besides, low CAR was correlated with more severe depressive symptoms and worse sleep quality. There was no difference in serum BDNF levels between groups with distinct sleep quality. Taken together, our results showed a relationship between changes in CAR and in sleep quality in patients with treatment-resistant depression, which were correlated with the severity of disease, suggesting that cortisol could be a physiological link between sleep disturbance and major depression.Artigo Moderators of ayahuasca’s biological antidepressant action(Frontiers Media SA, 2022-12) Sousa Júnior, Geovan Menezes de; Tavares, Vagner Deuel de Oliveira; Galvão, Ana Cecília de Menezes; Almeida, Raíssa Nóbrega de; Fontes, Fernanda Palhano Xavier de; Soares, Bruno Lobão; Freire, Fúlvio Aurélio de Morais; Nunes, Emerson Arcoverde; Oliveira, João Paulo Maia de; Perkins, Daniel; Sarris, Jerome; Araujo, Draulio Barros de; Coelho, Nicole Leite GalvãoIntroduction: The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol (SC), serum interleukin 6 (IL-6), plasma C-reactive protein (CRP), and salivary cortisol awakening response (CAR). Methods: Results were analyzed 2 days after the psychedelic intervention (ayahuasca) versus placebo in both patients with treatment-resistant depression and healthy volunteers. These measures were assessed as part of a randomized double-blinded, placebo-controlled trial (n = 72). Results: Results revealed that larger reductions of depressive symptoms during the dosing session significantly moderated higher levels of SC in patients. Whereas lesser changes in salivary cortisol levels during the ayahuasca intervention were related to higher BDNF levels in patients with a larger clinical response in the reduction in depressive symptoms. No moderator was found for patient's CAR, IL-6, and CRP responses to ayahuasca and for all biomarker responses to ayahuasca in healthy controls and in the placebo group. Discussion: In summary, some specific emotional and physiological parameters during experimental ayahuasca session were revealed as critical moderators of the improvement of major depression biomarkers, mainly BDNF and SC two days after ayahuasca intake. These findings contribute to paving the way for future studies investigating the biological antidepressant response to psychedelic therapyArtigo Modulation of serum brain-derived neurotrophic factor by a single dose of Ayahuasca: observation from a randomized controlled trial(2019-06-04) Almeida, Raíssa Nóbrega de; Galvão, Ana Cecília de Menezes; Silva, Flávia Santos da; Silva, Erick Allan dos Santos; Palhano-Fontes, Fernanda; Maia-de-Oliveira, João Paulo; Araújo, Dráulio Barros de; Lobão-Soares, Bruno; Galvão-Coelho, Nicole LeiteSerotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as suggested in a recent randomized controlled trial with ayahuasca for treatment-resistant depression. Preclinical and clinical studies have suggested that serum brain-derived neurotrophic factor (BDNF) levels increase after treatment with serotoninergic antidepressants, but the exact role of BDNF as a biomarker for diagnostic and treatment of major depression is still poorly understood. Here we investigated serum BDNF levels in healthy controls (N = 45) and patients with treatment-resistant depression (N = 28) before (baseline) and 48 h after (D2) a single dose of ayahuasca or placebo. In our sample, baseline serum BDNF levels did not predict major depression and the clinical characteristics of the patients did not predict their BDNF levels. However, at baseline, serum cortisol was a predictor of serum BDNF levels, where lower levels of serum BDNF were detected in a subgroup of subjects with hypocortisolemia. Moreover, at baseline we found a negative correlation between BDNF and serum cortisol in volunteers with eucortisolemia. After treatment (D2) we observed higher BDNF levels in both patients and controls that ingested ayahuasca (N = 35) when compared to placebo (N = 34). Furthermore, at D2 just patients treated with ayahuasca (N = 14), and not with placebo (N = 14), presented a significant negative correlation between serum BDNF levels and depressive symptoms. This is the first double-blind randomized placebo-controlled clinical trial that explored the modulation of BDNF in response to a psychedelic in patients with depression. The results suggest a potential link between the observed antidepressant effects of ayahuasca and changes in serum BDNF, which contributes to the emerging view of using psychedelics as an antidepressant. This trial is registered at http://clinicaltrials.gov (NCT02914769).